| Literature DB >> 25452691 |
Md Sarowar Jahan1, Md Jahirul Islam2, Rehana Begum3, Ruhul Kayesh3, Asma Rahman4.
Abstract
A rapid and stability-indicating reversed phase high-performance liquid chromatography (RP-HPLC) method was developed for simultaneous quantification of paracetamol and ibuprofen in their combined dosage form especially to get some more advantages over other methods already developed for this combination. The method was validated according to United States Pharmacopeia (USP) guideline with respect to accuracy, precision, specificity, linearity, solution stability, robustness, sensitivity, and system suitability. Forced degradation study was validated according to International Conference on Harmonisation (ICH). For this, an isocratic condition of mobile phase comprising phosphate buffer (pH 6.8) and acetonitrile in a ratio of 65:35, v/v at a flow rate of 0.7 mL/minute over RP C18 (octadecylsilane (ODS), 150 × 4.6 mm, 5 μm, Phenomenex Inc.) column at ambient temperature was maintained. The method showed excellent linear response with correlation coefficient (R (2)) values of 0.999 and 1.0 for paracetamol and ibuprofen respectively, which were within the limit of correlation coefficient (R (2) > 0.995). The percent recoveries for two drugs were found within the acceptance limit of (97.0-103.0%). Intra-and inter-day precision studies of the new method were less than the maximum allowable limit percentage of relative standard deviation (%RSD) ≤ 2.0. Forced degradation of the drug product was carried out as per the ICH guidelines with a view to establishing the stability-indicating property of this method and providing useful information about the degradation pathways, degradation products, and how the quality of a drug substance and drug product changes with time under the influence of various stressing conditions. The degradation of ibuprofen was within the limit (5-20%, according to the guideline of ICH), while paracetamol showed <20% degradation in oxidation and basic condition.Entities:
Keywords: RP-HPLC; ibuprofen; paracetamol; stability-indicating
Year: 2014 PMID: 25452691 PMCID: PMC4237153 DOI: 10.4137/ACI.S18651
Source DB: PubMed Journal: Anal Chem Insights ISSN: 1177-3901
Figure 1Structure of (A) paracetamol and (B) ibuprofen.
Newly developed RP-HPLC method.
| Mobile phase: Phosphate buffer (pH 6.8): Acetonitrile = 65:35, v/v |
| Column: C18 (150 × 4.6 mm, 5 μ, Phenomenex Inc.) |
| Flow rate: 0.7 mL/min |
| Wave length: 222 nm |
| Retention time: Paracetamol: 2.8 ± 0.1 min, Ibuprofen: 4.7 ± 0.1 min |
| Tailing factor: Paracetamol: 1.3, Ibuprofen: 1.1 |
Figure 2Chromatograms of blank, standard, and sample.
Figure 3Peak purity of paracetamol and ibuprofen.
Results of solution stability.
| DAY | ROOM TEMPERATURE | REFRIGERATOR | ||
|---|---|---|---|---|
| PARA | IBU | PARA | IBU | |
| Day 1 | 1548146 | 782314 | 1548146 | 782314 |
| Day 2 | 1540987 | 70193 | 1542538 | 779734 |
| Day 3 | 1538988 | 765330 | 1541885 | 779556 |
| %RSD | 0.312 | 1.13 | 0.223 | 0.198 |
Summary of stress degradation study.
| DRUG | % OF DEGRADATION AGAINST FRESHLY PREPARED STANDARD | ||||
|---|---|---|---|---|---|
| ACID | BASE | WATER | OXIDATION | REDUCTION | |
| PARA | 19.9 | 32.5 | 2.02 | 53.4 | 2.83 |
| IBU | 0 | 15.9 | 1.97 | 7.38 | 1.62 |
Notes:
Mean of three runs.
Figure 4Chromatograms of stressed condition, clockwise from top-left corner: acid, base, reduction, and oxidation. Peaks of paracetamol and ibuprofen were identified by their retention time, and rest of the peaks was of unknown degradants.
Figure 5Linearity curve of (A) paracetamol and (B) ibuprofen.
Accuracy (% recovery) of paracetamol and ibuprofen.
| INJECTED CONC. OF PARACETAMOL (μg/mL) | MEAN RECOVERED CONC. OF PARACETAMOL (μg/mL) | % RECOVERY OF PARACETAMOL | INJECTED CONC. OF IBUPROFEN (μg/mL) | MEAN RECOVERED CONC. OF IBUPROFEN (μg/mL) | % RECOVERY OF IBUPROFEN |
|---|---|---|---|---|---|
| 40 | 40.48 | 101.2 | 16 | 16.17 | 101.1 |
| 45 | 45.23 | 100.5 | 18 | 18.07 | 100.4 |
| 50 | 49.95 | 99.9 | 20 | 20.04 | 100.2 |
Results of method validation parameters.
| PARAMETERS | LIMITS | PARACETAMOL | IBUPROFEN |
|---|---|---|---|
| Linear equation | y = 32767x–88823 | y = 32950x–595 | |
| Correlation coefficient ( | ≥0.995 | 0.999 | 1.00 |
| Linearity range | 25–100 μg/mL | 10–40 μg/mL | |
| Precision(intra-day) | %RSD < 2% | ||
| Day 1, Analyst 1, Column 1 | 0.956% | 0.821% | |
| Day 2, Analyst 2, Column 2 | 1.344% | 1.937% | |
| Day 3, Analyst 3, Column 3 | 1.987% | 1.124% | |
| Precision(inter-day): | %RSD < 3% | 2.11% | 2.034% |
| LOD | S/N = 3:1 | 2.3 μg/mL | 0.213 μg/mL |
| LOQ | S/N = 10:1 | 7.9 μg/mL | 0.711 μg/mL |
Note:
Mean of six runs.
System suitability parameters.
| PARAMETER | PARACETAMOL | IBUPROFEN | USP LIMIT |
|---|---|---|---|
| %RSD of tR | 0.225 | 0.114 | ≤2% |
| %RSD of area | 0.223 | 0.198 | ≤2% |
| Tailing factor | 1.3 | 1.1 | ≤2.0 |
| Resolution | – | 6.5 | ≥2.0% |
| Theoretical plate | 2100 | 3743 | ≥2000 |
| Peak purity index | 1.00 | 1.00 | ≥0.98 |
Notes:
Mean of six runs.
Resolution with respect to former peak.
Summary of robustness.
| PARAMETER CHANGES | ACTUAL VALUES | RETENTION TIME | TAILING FACTOR | PEAK PURITY | |||
|---|---|---|---|---|---|---|---|
| PARA | IBU | PARA | IBU | PARA | IBU | ||
| ph ±0.4 | 7.2 | 2.9 | 4.1 | 1.2 | 1.1 | 1.00 | 1.00 |
| 6.2 | 2.4 | 5.4 | 1.3 | 1.2 | 1.00 | 1.00 | |
| Flow rate ±0.3 | 1.0 | 1.6 | 3.1 | 1.1 | 1.2 | 0.99 | 0.99 |
| 0.4 | 3.8 | 6.3 | 1.5 | 1.3 | 1.00 | 1.00 | |
| Wave length ±10 | 212 | 2.8 | 4.7 | 1.3 | 1.1 | 1.00 | 1.00 |
| 232 | 2.7 | 4.7 | 1.3 | 1.1 | 1.00 | 1.00 | |
| Organic concentration ±3.5 | 38.5% | 2.1 | 4.2 | 1.2 | 1.1 | 0.99 | 0.99 |
| 31.5% | 3.0 | 12.4 | 1.3 | 1.2 | 1.00 | 0.99 | |